Zobrazeno 1 - 10
of 69
pro vyhledávání: '"Claude Ribot"'
Publikováno v:
Revue du Rhumatisme. 77:378-381
Resume Objectifs Le but de cette etude descriptive etait d’evaluer le risque fracturaire par le score Frax™ chez 494 femmes non traitees en debut de menopause (45–60 ans) en fonction de la prise en charge proposee. Methodes Le risque fracturair
Publikováno v:
Joint Bone Spine. 77:345-348
To evaluate FRAX 10-year fracture probabilities depending on the recommended management strategy in early postmenopausal women who were untreated at baseline.We conducted a descriptive study in 494 untreated women aged 45-60 years seen for the first
Autor:
F. Tremollieres, Claude Ribot
Publikováno v:
Maturitas. 65:348-351
It is widely recognized that bone mineral density (BMD) is one of the best predictors of osteoporotic fractures. Sex hormone status clearly affects bone either directly or indirectly and a longer estrogen exposure appears to be a major determinant of
Autor:
Nicolas Drewniak, Florence Trémollières, Jean-Michel Pouilles, Claude Ribot, Patricia Dargent-Molina, Jacques Laparra
Publikováno v:
Journal of Bone and Mineral Research
Journal of Bone and Mineral Research, American Society for Bone and Mineral Research, 2010, 25 (5), pp.1002-9. ⟨10.1002/jbmr.12⟩
J Bone Miner Res
J Bone Miner Res, 2010, 25 (5), pp.1002-9. 〈10.1002/jbmr.12〉
Journal of Bone and Mineral Research, 2010, 25 (5), pp.1002-9. ⟨10.1002/jbmr.12⟩
Journal of Bone and Mineral Research, American Society for Bone and Mineral Research, 2010, 25 (5), pp.1002-9. ⟨10.1002/jbmr.12⟩
J Bone Miner Res
J Bone Miner Res, 2010, 25 (5), pp.1002-9. 〈10.1002/jbmr.12〉
Journal of Bone and Mineral Research, 2010, 25 (5), pp.1002-9. ⟨10.1002/jbmr.12⟩
International audience; The aim of this prospective study was (1) to identify significant and independent clinical risk factors (CRFs) for major osteoporotic (OP) fracture among peri- and early postmenopausal women, (2) to assess, in this population,
Publikováno v:
Journal of Bone and Mineral Research. 6:997-1002
This study evaluated the performance of dual-energy x-ray absorptiometry (DEXA) with regard to (1) the correlation with dual-photon absorptiometry (DPA), (2) the ability to discriminate between normal and osteoporotic patients, and (3) long-term repr
Autor:
Mario Passeri, Perez Ramon Cano, Olof Johnell, Claude Ribot, Erik Allander, L. Elffors, Carlo Gennari, Aurelio Rapado, Guzin Dilsen, George P. Lyritis, L. Miravet, John A. Kanis, Bo Gullberg, Lopes Antonio Vaz, Jan Dequeker, Gianfranco Mazzuoli
Publikováno v:
Journal of Bone and Mineral Research. 10:1802-1815
The aims of this study were to determine common international risk factors for hip fracture in women aged 50 years or more. We studied women aged 50 years or more who sustained a hip fracture in 14 centers from Portugal, Spain, France, Italy, Greece,
Autor:
Florence Trémollières, Claude Ribot
Publikováno v:
La Presse Médicale. 35:1557-1563
The consequences to the bone of estrogen deficiency are early and irreversible. Effective prevention of postmenopausal osteoporosis at the individual level requires early screening of women at risk of fractures and their early treatment. Hormone trea
Autor:
Claude Ribot
Publikováno v:
Revue du Rhumatisme. 73:812-816
Publikováno v:
Revue du Rhumatisme. 73:32-38
Resume Les estrogenes jouent un role primordial dans le controle de la mineralisation du tissu osseux qui possede tous les elements necessaires au metabolisme (systemes enzymatiques) et a la reponse (recepteurs Erα, ERs) aux estrogenes. Apres la men
Autor:
N Verbruggen, Piet Geusens, Mary E. Melton, Keavy A. Gaines, Philip N. Sambrook, JA Solimano, Claude Ribot, J Ferrer-Barriendos
Publikováno v:
Journal of Internal Medicine. 255:503-511
Objectives. Alendronate and raloxifene are antiresorptive agents with different mechanisms of action, each used to treat osteoporosis in postmenopausal women. This study was undertaken to compare the efficacy and tolerability of alendronate to raloxi